About non-small cell lung cancer therapeutics
Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.
Technavio's analysts forecast the global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer.
Technavio's report, Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global non-small cell lung cancer therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• Europe
Key vendors
• AstraZeneca
• Celgene
• Eli Lilly
• F. Hoffmann-La Roche
• Pfizer
Other prominent vendors
• Abbvie
• Aetna
• Agennix
• Amgen
• BetaPharma
• Bionumerik Pharmaceuticals
• Boehringer Ingelheim
• Bristol-Myers Squibb
• CBT Pharma
• Celldex Therapeutics
• Dainippon Pharma
• Eisai Pharmaceuticals
• GlaxoSmithKline
• Helsinn
• IMClone Systems
• IsisPharma
• Kadmon
• Kyowa Hakko Kirin
• MabVax Therapeutics
• Merck
• Novartis
• OncoGenex
• OSI Pharmaceuticals
• Peregrine
• Pierre Fabre
• Qiagen
• Sanofi
• Synta Pharmaceuticals
• Teva Pharmaceuticals
Key market driver
• Promising drug pipeline
• For a full, detailed list, view our report
Key market challenge
• High cost of therapy
• For a full, detailed list, view our report
Key market trend
• Personalized medicine
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Product profiles
PART 05: Introduction
Key market highlights
PART 06: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Diagnosis
Staging
Treatment
Epidemiology
PART 07: Pipeline portfolio
Information on pipeline candidates
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by molecule type
Biologics
Small molecules
PART 10: Market segmentation by route of administration
Oral
Parenteral
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
Competitive scenario
Market analysis 2014
Other prominent vendors
PART 18: Key vendor analysis
AstraZeneca
Celgene
Eli Lilly
F. Hoffmann-La Roche
Pfizer
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of non-small cell lung cancer
Exhibit 03: Gene mutations in non-small cell lung cancer
Exhibit 04: Risk factors for non-small cell lung cancer
Exhibit 05: Signs and symptoms of non-small cell lung cancer
Exhibit 06: Tests for diagnosis of non-small cell lung cancer
Exhibit 07: Staging of non-small cell lung cancer
Exhibit 08: Management of non-small cell lung cancer
Exhibit 09: Types of radiation therapy for non-small cell lung cancer
Exhibit 10: Photodynamic therapy uses light to actuate a drug in the body, which kills abnormal cells.Non-small cell lung cancer treatment algorithm
Exhibit 11: Phase III pipeline molecules for non-small cell lung cancer
Exhibit 12: Global non-small cell lung cancer therapeutics market 2014-2019 ($ billions)
Exhibit 13: Five forces analysis
Exhibit 14: Global non-small cell lung cancer therapeutics market segmentation by molecule type
Exhibit 15: Global non-small cell lung cancer therapeutics market segmentation by route of administration
Exhibit 16: Global non-small cell lung cancer market by geographical segmentation 2014
Exhibit 17: Impact of drivers
Exhibit 18: Impact of drivers and challenges
Exhibit 19: F. Hoffmann-La Roche: Global YoY growth and revenue of Avastin 2011-2014 ($ millions)
Exhibit 20: F. Hoffmann-La Roche: Key takeaways
Exhibit 21: Alimta: Global YoY growth and revenue 2011-2014 ($ millions)
Exhibit 22: Gemzar: Global YoY growth and revenue 2008-2011 ($ millions)
Exhibit 23: Eli Lilly: Key takeaways
Exhibit 24: Abraxane: Global YoY growth and revenue 2011-2014 ($ millions)
Exhibit 25: Celgene: Key takeaways
Exhibit 26: Iressa: Global YoY growth and revenue 2011-2014 ($ millions)
Exhibit 27: Iressa: YoY growth and revenue in Western Europe 2011-2014 ($ millions)
Exhibit 28: Iressa: YoY growth and revenue in established ROW 2011-2014 ($ millions)
Exhibit 29: Iressa: YoY growth and revenue in emerging markets 2011-2014 ($ millions)
Exhibit 30: AstraZeneca: Key takeaways
Exhibit 31: Xalkori: Global YoY growth and revenue 2012-2014 ($ millions)
Exhibit 32: Pfizer: Key takeaways
Exhibit 33: AstraZeneca: Business segmentation by revenue 2014
Exhibit 34: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 35: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 36: Celgene: Product segmentation by revenue 2014
Exhibit 37: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 38: Celgene: Geographical segmentation by revenue 2014
Exhibit 39: Eli Lilly: Business segmentation by revenue 2014
Exhibit 40: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 41: Eli Lilly: Geographical segmentation by revenue 2014
Exhibit 42: F. Hoffmann-La Roche: Business segmentation by revenue 2014
Exhibit 43: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 45: Pfizer: Business segmentation by revenue 2014
Exhibit 46: Pfizer: Geographical segmentation by revenue 2014
